DBV restructuring claims 200 jobs as it beats out a path toward peanut patch OK

Regulatory troubles around its peanut allergy treatment have hurt DBV Technologies bad.

It became even clearer Thursday morning as the French biotech disclosed the scope of a global restructuring it announced back in June. More than 200 jobs are being cut, leaving a team of 90 to carry on with the hard task of scoring approval for its Viaskin Peanut patch.